FEEL TECH BIO

1079-20, Charyeonggogae-ro, Gwangdeok-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Korea

Tel.: 82) 31-707-2112 / Fax: 82) 31-707-0990 / info@feeltech.co.kr

# Manufacturer's Declaration

in relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to

- the validity of certificates issued under Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) *and/or*[1]
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

| | |
|---|---|
| Manufacturer name | FEELTECH BIO Co.,Ltd. |
| Manufacturer address and contact details | 1079-20, Charyeonggogae-ro,Gwangdeok-myeon,Dongnam-gu,Cheonan-si,Chungcheongnam-do, KOREA (Zip code 31223) |
| Single Registration Number (SRN) (if available) | KR-MF-000032555 |

| | |
|---|---|
| Authorised Representative name (if applicable) | CMC Medicaldevices & Drugs S.L. |
| Authorised Representative address and contact details | C/Horacio Lengo N 18 CP 29006, Málaga-Spain |
| Single Registration Number (SRN) (if available) | ES-AR-000000293 |

| | |
|---|---|
| Notified body name (if applicable) | □ See attached schedule |
| Notified body number (if applicable) | □ See attached schedule |

[1] The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.

FEEL TECH BIO

1079-20, Charyeonggogae-ro, Gwangdeok-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Korea

Tel.: 82) 31-707-2112 / Fax: 82) 31-707-0990 / info@feeltech.co.kr

| | |
|---|---|
| Directive Certificate number(s) to which this confirmation is made (if applicable) | □ See attached schedule |
| Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable) | □ See attached schedule |
| End date of extended validity/transition period | □ See attached schedule |

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** (or see attached schedule, if multiple certificates) the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*[2]
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➢ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

  ☐ Expired/expires *after* 20 March 2023:

  ☐ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.

➢ **Quality Management System (QMS)**

☐ A QMS in accordance with Article 10(9) MDR is in place.

➢ **Device(s) as listed in the attached schedule**

- The device(s) continue to comply with the MDD.

[2] The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body

1079-20, Charyeonggogae-ro, Gwangdeok-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Korea
Tel.: 82) 31-707-2112 / Fax: 82) 31-707-0990 / info@feeltech.co.kr

- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

**Signed for and on behalf of the manufacturer:**

Full Company Name: FEELTECH BIO Co.,Ltd.

Location & Date: 07.05.2024

Signature, Print Name, Title: QMR Lim Jae Hyeoung

Contact Details (at least email): ftjhlwin @naver.com

FEEL TECH BIO

1079-20, Charyeonggogae-ro, Gwangdeok-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Korea

Tel.: 82) 31-707-2112 / Fax: 82) 31-707-0990 / info@feeltech.co.kr

**Schedule of Devices**

The above Manufacturer's Declaration is valid for the following devices:

| **Identification of the device(s)**[3] (e.g., device name, family/group name device model or catalogue number) | **Directive Certificate number(s) to which this confirmation is made** (if applicable) | **Original expiry date as indicated on the Directive Certificate (s) prior to the extension of the validity** (if applicable) | **Notified Body name and number that issued the Directive Certificate** (if applicable) | **Notified Body name and number where the MDR application was lodged/contract signed** (if applicable) | **End date of extended validity / transition period** | **Substitute Device(s)** (if applicable) |
|---|---|---|---|---|---|---|
| **Sterile single use insulin syringe (0.3 to 1.0ml)**<br><br>**Basic UDI: 88000451001MU** | **IT273004** | **26/05/2024** | **Notified Body name: Bureau Veritas Italia S.p.A Notified Body number: 1370** | **Notified Body name: UDEM Adriatic d.o.o Notified Body number: 2696** | **31/12/2028** | **Not applicable** |

[3] for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)